Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Johnson and Johnson
Baxter
McKinsey
Dow

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR GLUTAMINE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Glutamine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000925 ↗ A Study to Evaluate High Protein Supplementation in HIV-Positive Patients With Stable Weight Loss Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 1999-05-01 The purpose of this study is to determine whether a high-quality protein food supplement will help HIV-positive patients maintain, and possibly gain, muscle mass. Many HIV-positive patients lose weight that they are then unable to regain. This may be because patients are not eating enough protein or are not eating the right kinds of protein. The protein eaten in foods (such as meat, eggs, or beans) may not be able to make up for the amount of protein lost due to HIV infection. This study gives patients high-quality protein food supplements to help them maintain and/or gain weight.
NCT00005775 ↗ Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants Completed National Center for Research Resources (NCRR) Phase 3 1999-07-01 This large multicenter double-masked clinical trial tested whether supplementation of standard neonatal parenteral nutrition with glutamine would reduce the risk of death or late-onset sepsis in extremely-low-birth-weight (ELBW, less than or equal to 1000 gm) infants. Neonates with birth weights of 401-1000gm were randomized to standard TrophAmine or TrophAmine supplemented with glutamine before 72 hours and continued until the infants are tolerating full enteral feedings.
NCT00005775 ↗ Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants Completed NICHD Neonatal Research Network Phase 3 1999-07-01 This large multicenter double-masked clinical trial tested whether supplementation of standard neonatal parenteral nutrition with glutamine would reduce the risk of death or late-onset sepsis in extremely-low-birth-weight (ELBW, less than or equal to 1000 gm) infants. Neonates with birth weights of 401-1000gm were randomized to standard TrophAmine or TrophAmine supplemented with glutamine before 72 hours and continued until the infants are tolerating full enteral feedings.
NCT00005889 ↗ Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion Unknown status Baylor College of Medicine N/A 1999-10-01 RATIONALE: Very low birth weight infants have problems maintaining normal blood sugar levels. Gluconeogenesis is the production of sugar from amino acids and fats. The best combination of amino acids, fat, and sugar to help very low birth weigh infants maintain normal blood sugar levels is not yet known. PURPOSE: Clinical trial to study how very low birth weight infants break down amino acids, fat, and sugar given by intravenous infusion, and the effect of different combinations of nutrients on the infants' ability to maintain normal blood sugar levels.
NCT00005889 ↗ Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion Unknown status National Center for Research Resources (NCRR) N/A 1999-10-01 RATIONALE: Very low birth weight infants have problems maintaining normal blood sugar levels. Gluconeogenesis is the production of sugar from amino acids and fats. The best combination of amino acids, fat, and sugar to help very low birth weigh infants maintain normal blood sugar levels is not yet known. PURPOSE: Clinical trial to study how very low birth weight infants break down amino acids, fat, and sugar given by intravenous infusion, and the effect of different combinations of nutrients on the infants' ability to maintain normal blood sugar levels.
NCT00006994 ↗ S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat Terminated National Cancer Institute (NCI) Phase 3 2001-11-01 RATIONALE: Glutamine may be effective in decreasing side effects, such as inflammation of the mouth and throat, caused by radiation therapy. The effectiveness of glutamine for mucositis is not yet known. PURPOSE: Randomized phase III trial to determine the effectiveness of glutamine in treating patients who develop mucositis following radiation therapy for newly diagnosed cancer of the mouth or throat.
NCT00006994 ↗ S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat Terminated Southwest Oncology Group Phase 3 2001-11-01 RATIONALE: Glutamine may be effective in decreasing side effects, such as inflammation of the mouth and throat, caused by radiation therapy. The effectiveness of glutamine for mucositis is not yet known. PURPOSE: Randomized phase III trial to determine the effectiveness of glutamine in treating patients who develop mucositis following radiation therapy for newly diagnosed cancer of the mouth or throat.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Glutamine

Condition Name

Condition Name for Glutamine
Intervention Trials
Lymphoma 9
Bipolar Depression 7
Critical Illness 6
Schizophrenia 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Glutamine
Intervention Trials
Depression 13
Depressive Disorder 11
Bipolar Disorder 9
Mucositis 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Glutamine

Trials by Country

Trials by Country for Glutamine
Location Trials
United States 273
China 9
India 7
Egypt 6
Canada 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Glutamine
Location Trials
Texas 26
New York 17
California 17
Massachusetts 14
Tennessee 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Glutamine

Clinical Trial Phase

Clinical Trial Phase for Glutamine
Clinical Trial Phase Trials
Phase 4 24
Phase 3 33
Phase 2/Phase 3 13
[disabled in preview] 98
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Glutamine
Clinical Trial Phase Trials
Completed 82
Terminated 26
Recruiting 25
[disabled in preview] 44
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Glutamine

Sponsor Name

Sponsor Name for Glutamine
Sponsor Trials
M.D. Anderson Cancer Center 14
National Cancer Institute (NCI) 9
Emmaus Medical, Inc. 7
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Glutamine
Sponsor Trials
Other 240
Industry 50
NIH 40
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Harvard Business School
Medtronic
Mallinckrodt
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.